{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:10:44Z","timestamp":1793686244033,"version":"4.5.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41582-021-00547-z","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:05:18Z","timestamp":1629716718000},"page":"597-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Getting specific: targeting Fc receptors in myasthenia gravis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-708X","authenticated-orcid":false,"given":"Jan D.","family":"L\u00fcnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"547_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","volume":"296","author":"KV Toyka","year":"1977","unstructured":"Toyka, K. V. et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296, 125\u2013131 (1977).","journal-title":"N. Engl. J. Med."},{"key":"547_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Dis. Primers 5, 30 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"547_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas, M. C. Immunotherapy in myasthenia gravis in the era of biologics. Nat. Rev Neurol. 15, 113\u2013124 (2019).","journal-title":"Nat. Rev Neurol."},{"key":"547_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard, J. F. Jr et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"547_CR5","unstructured":"argenx. argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis. argenx https:\/\/www.argenx.com\/news\/argenx-announces-fda-acceptance-bla-filing-efgartigimod-treatment-generalized-myasthenia (2021)."},{"key":"547_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling, P. et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Sci. Transl Med. 9, eaan1208 (2017).","journal-title":"Sci. Transl Med."},{"key":"547_CR7","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts, P. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J. Clin. Invest. 128, 4372\u20134386 (2018).","journal-title":"J. Clin. Invest."},{"key":"547_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD Lunemann","year":"2015","unstructured":"Lunemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80\u201389 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"547_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/acn3.51136","volume":"7","author":"BL Vollmer","year":"2020","unstructured":"Vollmer, B. L. et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann. Clin. Transl Neurol. 7, 1477\u20131487 (2020).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"547_CR10","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard, J. F. Jr et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92, e2661\u2013e2673 (2019).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00547-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00547-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00547-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T13:32:02Z","timestamp":1632835922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00547-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1038\/s41582-021-00547-z","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"23 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.L. has received speaker fees, research support, and\/or served on advisory boards at the Swiss National Science Foundation, the German Research Foundation, the Swiss Multiple Sclerosis Society, AbbVie, Alexion, ArgenX, Bayer AG, Biogen Inc, F. Hoffmann-La Roche, Merck & Co., Novartis AG and Sanofi Genzyme.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}